METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for MASH-Related cirrhosis in early trial
Disease control CompletedThis study tested a new medicine called BI 770371 in 28 people with liver scarring (cirrhosis) caused by MASH, a fatty liver disease. Participants received either the drug or a placebo as an IV infusion every 3 weeks for 12 weeks. The main goal was to see if the drug is safe and …
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
MASH awareness survey completed: what do patients and doctors really know?
Knowledge-focused CompletedThis study used online questionnaires to find out how much healthcare providers, people with MASH, and those at risk know about the links between MASH and heart, kidney, and metabolic diseases. Over 1300 participants from five countries took part. The goal was to gather informati…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated May 04, 2026 16:31 UTC